Cotellic Combination Therapy Effective in Melanoma

Final survival data from the Phase III coBRIM clinical trial showed the drug cobimetinib (Cotellic) used in combination with vemurafenib (Zelboraf) helped patients with previously untreated BRAF V600 mutation-positive advanced melanoma live significantly longer compared to Zelboraf alone.